 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...2223242526272829303132...3637» |
- | Cotellic (cobimetinib) / Exelixis, Roche, Alecensa (alectinib) / Roche
Trial completion date, Trial primary completion date, Metastases: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC (clinicaltrials.gov) - Aug 21, 2020
P1/2, N=31, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Aug 2020 --> Nov 2022 | Trial primary completion date: Aug 2019 --> Nov 2021
- || Alecensa (alectinib) / Roche
Trial completion date, Trial primary completion date, Metastases: Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea (clinicaltrials.gov) - Aug 19, 2020
P=N/A, N=167, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Aug 2020 --> Nov 2022 | Trial primary completion date: Aug 2019 --> Nov 2021 Trial completion date: Dec 2021 --> Jun 2021 | Trial primary completion date: Dec 2021 --> Jun 2021
- Alecensa (alectinib) / Roche
[VIRTUAL] A Case of Alectinib Cutaneous Toxicity and Results of a Desensitization Protocol () - Aug 19, 2020 - Abstract #AVAHO2020AVAHO_14;
His rash worsened resulting in a drug hold, treatment with oral prednisone, and a dose reductionto 300mg daily...Nonetheless, lorlatinib was discontinuedafter 4 weeks due to other intolerable side effects and hypertriglyceridemia.Pembrolizumab has a terminal half-life of 22 days with steady state reached at 16 weeks with every 3-week dosing...If hypersensitivityrecurs, switching to an alternate ALK TKI is warranted. However, if immunotherapy has been previouslyadministered without time for adequate washout, no TKI therapy may be tolerable.
- | Tabrecta (capmatinib) / Incyte, Novartis, Tepmetko (tepotinib) / EMD Serono, Alecensa (alectinib) / Roche
But, it progressed after ALECTINIB .. so single agent crizo may not sufficient .. I will add capmatinib or Tepotinib alongwith Alectinib.. (Twitter) - Aug 16, 2020
- ||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: Authors did switch alectinib to crizotinib for what appeared as a single liver mets progressive acquired ALKi resistance. Only short-lived partial response from crizotinib. I think it is v reasonable to continue ALKi with local ablative RT if only 1 AR lesion. Nice case still. (Twitter) - Aug 16, 2020
- ||| Tabrecta (capmatinib) / Incyte, Novartis, Alecensa (alectinib) / Roche
Any thoughts about switching to Capmatinib and continuing alectinib alternating days in these situations? @PatelOncology @LudaBazhenovaMD @LeciaSequist (Twitter) - Aug 16, 2020
- ||||| Alecensa (alectinib) / Roche
Clinical: Case report: Acquired exon14 MET mutation associated with resistance to alectinib in a patient with ALK rearranged NSCLC - JTO Clinical and Research Reports https://t.co/gPoGU4a666 (Twitter) - Aug 16, 2020
- |||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical, Next-Generation Sequencing: #OncoAlert Nice case report @JTOonline #JTOCRR by @nicogirardcurie reporting acquired METex14 mutation mediating early resistance (at 1y) to alectinib in #ALK NSCLC. Responded to crizotinib until a different MET mutation emerged. #NGS #LCSM @IASLC https://t.co/dCdLoH2j3h (Twitter) - Aug 11, 2020
- || Alecensa (alectinib) / Roche
Why wasn’t alectinib the SOC arm? Even if design predated 2017, most accruals surely took place after April 2017. (Twitter) - Aug 8, 2020
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors. (Pubmed Central) - Aug 8, 2020
This case supports the importance of both histopathologic assessment and comprehensive genomic profiling in selecting appropriate treatment for patients with refractory, metastatic, ALK oncogene-driven non-small cell lung cancer. Use of symptom-directed radiation in tandem with ALK inhibitors contributed to the disease and symptomatic control and prolonged survival in this patient.
- ||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Agree. However Brigatinib also belongs in the conversation with Alectinib. In fact for certain patients with specific gene mutations. Brigatinib appears better than Alectinib. (Twitter) - Aug 8, 2020
- ||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: You're being charitable with "last year's model". This trial has gone on forever, & crizotinib was beaten handily by alectinib several years ago. **A drug needs to be First, Fabulous (clearly better than what preceded it, in efficacy, tox, &/or cost), or... it's F*cked.** (Twitter) - Aug 8, 2020
- || Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Just educationally to learn as I know one should not do it but maybe there are examples where it could be interesting as I have seen it sometimes (eg. in IO trials)? Thinking also a bit of yesterday's #lorlatinib press release. How to compare the upcoming data against alectinib? (Twitter) - Aug 8, 2020
- |||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: Nice results; however, I think it's clear that while a med PFS of 25.8 months is far superior to crizotinib, which is a historical footnote as obviated prior 1st line therapy, it's no better & arguably inferior to what we already have as a global 1st line SoC in alectinib. #LCSM (Twitter) - Aug 8, 2020
- || Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
It would be hard to improve on already high icORR for both alectinib and brigatinib. Agree with @JackWestMD Toxicity would be the differentiator. (Twitter) - Aug 8, 2020
- | Alecensa (alectinib) / Roche
Do you mind me asking how long Alectinib worked? (Twitter) - Aug 7, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical, Preclinical: W/toxicity concerns of lorlatinib v. alectinib or brigatinib, that efficacy improvemt, especially over alectinib, will be a VERY high hurdle. Plus, improvement would need to offset loss of lorlatinib option after acquired resistance on one of the other agents. (so NOT likely) (Twitter) - Aug 7, 2020
- ||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Another shocking trial result. Sarcasm aside, it will be interesting to see if the HR and/or PFS results are good enough to dethrone alectinib or brigatinib as 1L options. #LCSM https://t.co/yGlA4cvUQi (Twitter) - Aug 7, 2020
- |||| Lorbrena (lorlatinib) / Pfizer, Libtayo (cemiplimab) / Sanofi, Regeneron, Alecensa (alectinib) / Roche
Unsurprising result. IMO, this is like cemiplimab >> chemo in high PD-L1 subgrp as 1L in adv NSCLC. Lateral move; so what? That lorlatinib is better than 1L SoC from 2017 is fine, but tox profile is a challenge; As you note, alectinib as today's 1L SoC is higher hurdle. $LCSM (Twitter) - Aug 5, 2020
- ||||| Alecensa (alectinib) / Roche
Reimbursement: What my take-away from this great thread is- do your best to get tissue but if not feasible in desperate situation/ effective/non-toxic tx- such as osi for EGFR/ alectinib for ALK etc- i can quote many of you + the Rolling Stones when arguing w insurance and will go for it! (Twitter) - Jul 31, 2020
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Observational data, Retrospective data, Journal: Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer. (Pubmed Central) - Jul 30, 2020
Use of symptom-directed radiation in tandem with ALK inhibitors contributed to the disease and symptomatic control and prolonged survival in this patient. This study provides initial information on real-world treatment patterns following the introduction of new ALK inhibitors, and supports the use of sequential ALK therapies.
- |||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Novel #ALK fusion partner, PPFIBP1-ALK, in met #PDAC w/initial response to #alectinib then PD w/acquired alectinib-resistant muts stabilized with #lorlatinib 3rd-gen #ALK inhibitor https://t.co/PjdyO3tuCl @DrHendifar @PancPathologist prev involved w/largest series of #ALK #PDAC (Twitter) - Jul 29, 2020
- | Alecensa (alectinib) / Roche
Journal: Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. (Pubmed Central) - Jul 29, 2020
This study provides initial information on real-world treatment patterns following the introduction of new ALK inhibitors, and supports the use of sequential ALK therapies. No abstract available
- |||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Novel ALK Fusion, PPFIBP1-ALK , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib https://t.co/V6Q2fBUARY (Twitter) - Jul 28, 2020
- | Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
Journal: Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. (Pubmed Central) - Jul 25, 2020
No abstract available No abstract available
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect? (Pubmed Central) - Jul 25, 2020
No abstract available No abstract available
- || Alecensa (alectinib) / Roche
Clinical, Journal: Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports. (Pubmed Central) - Jul 24, 2020
No abstract available Alectinib works very well in intracranial metastases and is assumed to be so on the ocular ones as well, with benefit for the patient in quality of life.
- Alunbrig (brigatinib) / Takeda
[VIRTUAL] Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2172;
Legal entity responsible for the study: Groupe Français de Pneumo-Cancérologie. Funding: Takeda.
- Lorbrena (lorlatinib) / Pfizer
[VIRTUAL] Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2148;
Funding: Has not received any funding. Clinical trial identification: not applicable
- Alunbrig (brigatinib) / Takeda
[VIRTUAL] Treatment duration and adherence in ALK+ non-small cell lung cancer patients treated with brigatinib following prior ALK TKI therapy in the US (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2147;
Legal entity responsible for the study: IQVIA, Inc. Funding: Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
- Alunbrig (brigatinib) / Takeda
[VIRTUAL] Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2130;
Legal entity responsible for the study: Takeda Pharmaceuticals International AG. Funding: Takeda Pharmaceuticals International AG.
- [VIRTUAL] Real-world treatment patterns and outcomes in patients (pts) with advanced, ALK+ non-small cell lung cancer (NSCLC) in Europe (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2120;
Legal entity responsible for the study: Medimix International. Funding: Medimix International.
- Alecensa (alectinib) / Roche
[VIRTUAL] Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2081;
P2/3
In the ALK+ cohort, investigator-assessed objective response rate (ORR) was 87.4% and 12-month progression-free survival (PFS) rate was 78.4% with alectinib...Funding: F. Hoffmann-La Roche Ltd. Clinical trial identification: NCT03178552.
- Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
[VIRTUAL] The value of detecting resistance through liquid biopsy (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1981;
P=N/A
Funding: Princess Margaret Cancer Foundation; Guardant Health. Clinical trial identification: NCT03576937.
- ||| Enrollment closed, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 24, 2020
P2a, N=765, Active, not recruiting, Sponsor: Genentech, Inc.
Clinical trial identification: NCT03576937. Recruiting --> Active, not recruiting
- | Journal: Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. (Pubmed Central) - Jul 21, 2020
Nowadays, several molecules are approved for the treatment of ALK+ NSCLC, either in first or further lines of systemic treatment. Several clinical trials are currently ongoing in order to define a potential role of ALK inhibitors in combination with novel anti-cancer agents, as well as monotherapy in neo- and adjuvant settings.
- ||||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Next-Generation Sequencing: Pt c ALK+ lung dx 10/18. Stopped alectinib due to pneumonitis. Started lorlatinib. Raynaud like phenomenon 4/20, assoc c cold. Ca prog 7/20. Blood ngs with eml4-alk, no other mut. PDL1=5% @JackWestMD @CharuAggarwalMD @LeciaSequist @StephenVLiu @PatelOncology @Jbauml @GlopesMd (Twitter) - Jul 20, 2020
- |||||| Clinical, Next-Generation Sequencing: Had a case of Alk rerranged NSCLC progressed on crizo->Ceritinib->Alectinib- >lorlatinib. NGS revealed AlK rearrangement with BRAF fusion .The response to Lorlatinib + Trametinib was fantabulous .Although one can call this anecdotal (Twitter) - Jul 20, 2020
- || Clinical, PK/PD data, Review, Journal: Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. (Pubmed Central) - Jul 9, 2020
Although the absorption, distribution, and excretion of anaplastic lymphoma kinase inhibitors are regulated by drug transporters, their transporter-mediated pharmacokinetics have not yet been elucidated in detail in patients with non-small-cell lung cancer. Further research to analyze the contribution of drug transporters to the pharmacokinetics of anaplastic lymphoma kinase inhibitors in patients with non-small-cell lung cancer will be helpful for understanding the mechanisms of the inter-individual differences in the pharmacokinetics of anaplastic lymphoma kinase inhibitors.
- || Alunbrig (brigatinib) / Takeda
Trial primary completion date, Metastases: ALTA-2: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (clinicaltrials.gov) - Jul 7, 2020
P2, N=104, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Further research to analyze the contribution of drug transporters to the pharmacokinetics of anaplastic lymphoma kinase inhibitors in patients with non-small-cell lung cancer will be helpful for understanding the mechanisms of the inter-individual differences in the pharmacokinetics of anaplastic lymphoma kinase inhibitors. Trial primary completion date: Jun 2020 --> Sep 2020
- || Alunbrig (brigatinib) / Takeda
Trial completion date, Trial primary completion date, Metastases: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors (clinicaltrials.gov) - Jul 7, 2020
P=N/A, N=160, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Jun 2020 --> Sep 2020 Trial completion date: May 2022 --> Nov 2023 | Trial primary completion date: Apr 2022 --> Oct 2023
- vinorelbine tartrate / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Granulocyte Colony-Stimulating Factor-Producing Anaplastic Lymphoma Kinase-Positive Lung Cancer (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_6124;
Gemcitabine/vinorelbine chemotherapy was administered but the lung cancer eventually exacerbated and the patient died 5 months after the first visit...Therefore, a marked increase in the WBC count at initial diagnosis can be indicative of G-CSF-producing lung cancer. Surgical resection should be considered as a first option in case of diagnosed G-CSF-producing lung cancer, because although ALK is positive, the response to medical treatment is expected to be poor.
- Alecensa (alectinib) / Roche
[VIRTUAL] Alectinib Induced Interstitial Pneumonitis / ILD (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3990;
This case highlights the importance of looking for drug-induced lung injury, detecting them early and intervening appropriately to prevent significant lung injury. Although, there have been reports of ILD associated with ALK inhibitors, alectinib induced interstitial pneumonitis/ILD is not very common.
- || Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical, Journal, Liquid Biopsy: Brief Report: Clinical Utility of Cerebrospinal Fluid Cell Free-DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. (Pubmed Central) - Jul 2, 2020
Liquid biopsy of CSF is more sensitive than plasma to detect targetable alterations, characterizing resistance mechanisms on progression and monitoring tumor response in ALK-rearranged NSCLC patients with LM. Thus CSF might be promising as a medium of liquid biopsy in LM.
- ||| Alecensa (alectinib) / Roche
Biomarker, Clinical, P3 data, Journal: Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study. (Pubmed Central) - Jun 30, 2020
Thus CSF might be promising as a medium of liquid biopsy in LM. Alectinib continues to demonstrate superior investigator-assessed PFS versus crizotinib in untreated ALK+ NSCLC, irrespective of EML4-ALK variant.
- ||| Biomarker, Enrollment open: NAUTIKA1: A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 29, 2020
P2, N=60, Recruiting, Sponsor: Genentech, Inc.
Alectinib continues to demonstrate superior investigator-assessed PFS versus crizotinib in untreated ALK+ NSCLC, irrespective of EML4-ALK variant. Not yet recruiting --> Recruiting
- || Review, Journal: Therapeutic strategies in advanced ALK positive non-small cell lung cancer (Pubmed Central) - Jun 28, 2020
The emergence of crizotinib drug resistance has prompted the development of next generation drugs including ceritinb, alectinib, brigatinib and lorlatinib. The ability to quickly develop targeted therapies against specific oncogenic drivers will require close co-operation between pathologists, pulmonologists and oncologists in the future to keep pace with drug discoveries and to define optimal therapeutic strategies.
- |||||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical, Preclinical: #CIOT20 Comprehensive updates on #ALK #NSCLC by @EnriquetaFelip. Alectinib with very impressive long term OS results. Brigatinib also very impressive in the 1L setting. Efficacy seen when ALK detected on ctDNA (BFAST). Next frontier is navigating acquired resistance. #LCSM (Twitter) - Jun 26, 2020
- | Journal: Drug discovery targeting anaplastic lymphoma kinase (ALK). (Pubmed Central) - Jun 26, 2020
This review provides an overview of the physiological and biological functions of ALK, the discovery and development of ALK drugs by focusing on their chemotypes, inhibitory activity, selectivity and resistance, as well as current status. Additionally, the mechanism of drug resistance and potential therapeutic strategies to overcome drug resistance are also summarized.
- || Tagrisso (osimertinib) / AstraZeneca
Biomarker, Trial completion date, Trial primary completion date, Metastases: Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (clinicaltrials.gov) - Jun 25, 2020
P2, N=182, Recruiting, Sponsor: AstraZeneca
Additionally, the mechanism of drug resistance and potential therapeutic strategies to overcome drug resistance are also summarized. Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023